Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans

JAMA. 2024 Jul 2;332(1):74-76. doi: 10.1001/jama.2024.8917.
No abstract available

Plain language summary

This study examines formulary coverage of brand-name adalimumab and biosimilars across Medicare Part D plans.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab* / economics
  • Adalimumab* / therapeutic use
  • Biosimilar Pharmaceuticals* / economics
  • Biosimilar Pharmaceuticals* / therapeutic use
  • Drugs, Generic / economics
  • Drugs, Generic / therapeutic use
  • Formularies as Topic*
  • Humans
  • Insurance Coverage* / economics
  • Insurance Coverage* / statistics & numerical data
  • Medicare Part D* / economics
  • Medicare Part D* / statistics & numerical data
  • United States / epidemiology

Substances

  • Adalimumab
  • Biosimilar Pharmaceuticals
  • Drugs, Generic